Literature DB >> 14763172

Carcinoma of the ovary.

A P Heintz1, F Odicino, P Maisonneuve, U Beller, J L Benedet, W T Creasman, H Y Ngan, S Pecorelli.   

Abstract

Entities:  

Mesh:

Year:  2003        PMID: 14763172     DOI: 10.1016/s0020-7292(03)90118-4

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


× No keyword cloud information.
  33 in total

1.  Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.

Authors:  Koji Matsuo; Michele L Eno; Edward H Ahn; Mian M K Shahzad; Dwight D Im; Neil B Rosenshein; Anil K Sood
Journal:  Am J Clin Oncol       Date:  2011-10       Impact factor: 2.339

2.  Uterine metastases in ovarian carcinoma: frequency and survival in women who underwent hysterectomy.

Authors:  Joseph Menczer; Angela Chetrit; Siegal Sadetzki
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

3.  Diagnostic and referral intervals for Manitoba women with epithelial ovarian cancer - the Manitoba Ovarian Cancer Outcomes (MOCO) study group: a retrospective cross-sectional study.

Authors:  Allison J Love; Pascal Lambert; Donna Turner; Robert Lotocki; Erin Dean; Shaundra Popowich; Alon D Altman; Mark W Nachtigal
Journal:  CMAJ Open       Date:  2017-02-07

4.  Outcome of Bowel Resection in Women with Advanced Ovarian Carcinoma.

Authors:  Ajit Sebastian; Anitha Thomas; Gigi Varghese; Bijesh Yadav; Rachel Chandy; Abraham Peedicayil
Journal:  Indian J Surg Oncol       Date:  2018-07-20

5.  Advanced Primary Epithelial Ovarian and Peritoneal Carcinoma-Does Diagnostic Accuracy of Preoperative CT Scan for Detection of Peritoneal Metastatic Sites Reflect into Prediction of Suboptimal Debulking? A Prospective Study.

Authors:  Kiran Bagul; D K Vijaykumar; Anupama Rajanbabu; Mitchelle Aline Antony; Venkatesan Ranganathan
Journal:  Indian J Surg Oncol       Date:  2017-02-18

6.  HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.

Authors:  Thea Eline Hetland; Arild Holth; Janne Kærn; Vivi Ann Flørenes; Claes G Tropé; Ben Davidson
Journal:  Virchows Arch       Date:  2012-04-04       Impact factor: 4.064

7.  Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.

Authors:  Anne-Katrin Zimmermann; Jochen Imig; Agnes Klar; Christoph Renner; Dimitri Korol; Daniel Fink; Sylvia Stadlmann; Gad Singer; Alexander Knuth; Holger Moch; Rosmarie Caduff
Journal:  Virchows Arch       Date:  2013-03-26       Impact factor: 4.064

8.  Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.

Authors:  Digant Gupta; Carolyn A Lammersfeld; Pankaj G Vashi; Donald P Braun
Journal:  J Ovarian Res       Date:  2010-10-12       Impact factor: 4.234

9.  Ascites specific inhibition of CD1d-mediated activation of natural killer T cells.

Authors:  Tonya J Webb; Robert L Giuntoli; Ophelia Rogers; Jonathan Schneck; Mathias Oelke
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

10.  The reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells.

Authors:  Zhi Jiang; Bao-An Chen; Guo-Hua Xia; Qiang Wu; Yu Zhang; Tie-Yan Hong; Wei Zhang; Jian Cheng; Feng Gao; Li-Jie Liu; Xiao-Mao Li; Xue-Mei Wang
Journal:  Int J Nanomedicine       Date:  2009-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.